The management recently emphasized that the objective was to make RenalGuard the standard for care in reduction of AKI. The milestones mentioned by the company on its website include the crucial interim results from the US pivotal clinical trials. Going forward, that will be a major step in increasing the acceptance of the product. Success or progress in the US trials will increase awareness about the product in the world markets. Currently, Europe is the main market for PLCSF, and it has a focus on that region. The product received favorable response from cardiologists at the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Several cardiologists were confident about the efficacy of the product, especially in patients undergoing Transcatheter Aortic Valve Implantation (TAVI). In that therapy, RenalGuard helps by maintaining a high urine output, while simultaneously making up for the fluid loss. Positive reception in Europe is crucial for the company as Europe remains its main commercial market. The company recently obtained a method patent for the product in US for “Patient Hydration Method. This was the 9th patent in US, and it also has one European, Canadian and Japanese patent for the product. However, there is a need to expedite the trials and make concrete progress on the commercial front so that the interest of the investors increases. The company had sold its product related to Heart Laser technology in 2011. That decision may pay off in the near future if there is some breakthrough in the US trials and there is wider acceptance in other parts of the world. In an important news, there were some changes in the board of directors with some old directors departing and some new directors joining in. The CEO was confident about the future, but investors need to see faster development on the ground.